Drug Markets/EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

3 NDCs across 1 manufacturers|0 Generic,3 Brand

Total NDCs

0G / 3B

Manufacturers

competing in market

Price Spread

$71.39 – $71.43

Up to 0% savings

7d Activity

9↓-6 flat

of 3 total NDCs

Monthly average NADAC price per unit, split by generic and brand

1 manufacturer producing EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

3 NDCs total, 3 shown

Drug ↕	NDC	Manufacturer ↕	Price	Market Outlier	Class	7d Change ↕	Therapeutic Class
DESCOVY 200-25 MG TABLET	61958200201	Gilead Sciences, Inc.	$71.4275 per EA	—	Brand	-0.01%	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
DESCOVY 200-25 MG TABLET	61958200202	Gilead Sciences, Inc.	$71.4275 per EA	—	Brand	-0.01%	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
DESCOVY 120-15 MG TABLET	61958200501	Gilead Sciences, Inc.	$71.3937 per EA	—	Brand	-0.03%	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor